로딩 중…
지수 로딩 중…
Green Cross Medical Science Corporation
142280· KOSDAQ· Health Care· Health Care Equipment & Services
₩2,615+5.02%
2026-08-04
Financials
Valuation Metrics
Green Cross Medical Science Corporation's Market Cap is ₩627B. At end of 2025 it was ₩960B. Ranked #1582 of 2,436 in KR market (top 65%), #927 of 1,649 on KOSDAQ (top 56%), #63 of 96 in Health Care Equipment & Services (top 66%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 62.66B KRW | KR#1,582/2,436 Sec#63/96 |
| Revenue | 105.48B KRW | KR#1,363/2,436 Sec#33/96 |
| Net Income | 4.41B KRW | KR#1,166/2,436 Sec#39/96 |
| Total Assets | 91.16B KRW | KR#1,817/2,436 Sec#56/96 |
| Net Assets | 46.60B KRW | KR#1,922/2,436 Sec#63/96 |
| Employees | 133 | KR#1,408/2,436 Sec#47/96 |
| Value | ||
| P/E | 14.21x | KR#942/2,436 Sec#27/96 |
| P/B | 1.34x | KR#1,719/2,436 Sec#54/96 |
| PEG | 0.31x | KR#595/2,436 Sec#22/96 |
| P/S | 0.59x | KR#1,052/2,436 Sec#11/96 |
| EV/EBITDA | 26.94x | KR#1,151/2,436 Sec#37/96 |
| FCF Yield | 3.95% | KR#939/2,436 Sec#26/96 |
| Profitability | ||
| ROE | 9.46% | KR#552/2,436 Sec#26/96 |
| ROA | 4.84% | KR#670/2,436 Sec#31/96 |
| Op. Margin | 2.54% | KR#1,290/2,436 Sec#47/96 |
| Revenue Growth | -11.07% | KR#1,904/2,436 Sec#75/96 |
| Earnings Growth | 46.43% | KR#589/2,436 Sec#23/96 |
| Financial Health | ||
| Debt Ratio | 95.62% | KR#315/2,436 Sec#12/96 |
| Total Debt | 10.58B KRW | KR#1,608/2,436 Sec#51/96 |
| FCF | 2.48B KRW | KR#1,049/2,436 Sec#30/96 |
| Cash | 956.1M KRW | KR#2,339/2,436 Sec#94/96 |
| Current Ratio | 1.17x | KR#1,624/2,436 Sec#77/96 |
| Net Debt/EBITDA | 3.59x | KR#1,001/2,436 Sec#40/96 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,436 Sec—/96 |
| Performance | ||
| 1Y Return | -34.71% | KR#1,697/2,436 Sec#53/96 |
| 1M Return | -11.80% | KR#1,865/2,436 Sec#71/96 |
| From 52W High | -60.74% | KR#1,748/2,436 Sec#63/96 |
| 1Y MDD | -61.56% | KR#1,494/2,436 Sec#48/96 |
| Trading | ||
| Volume | 120,981 shares | KR#829/2,436 Sec#34/96 |
| Foreign Own. | 2.14% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | 206 KRW | KR#1,192/2,436 Sec#40/96 |
| BPS | 2,048 KRW | KR#2,015/2,436 Sec#65/96 |
Company Info
동사는 2003년 체외진단용의약품 제조판매를 목적으로 설립되었고, 2015년 녹십자메디스를 인수하며 자회사로 편입하였음. 2019년 충북 음성에 국내 최대 혈액투석액 생산시설을 갖추었고, 다양한 진단시약 및 의료기기, 혈액투석액 사업을 영위하고 있음. 유전체분석과 AI를 활용한 다중 진단 플랫폼으로의 전환과 첨단 POCT 진단시스템 개발을 바탕으로 혁신을 추구하고 있음. 녹십자엠에스는 2003년에 설립되었으며 경기도 용인시에 본사를 두고 있습니다.